drugset / Trial / NCT00914602
An Exploratory Study of XP21279 (With Lodosyn®) and Sinemet® in Parkinson's Disease Subjects
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of the study is to assess the pharmacokinetics, pharmacodynamics, and safety of XP21279 sustained release formulation \[administered with Lodosyn® (carbidopa)\] and Sinemet® tablets in subjects with Parkinson's disease with Motor Fluctuations.
Timeline
- Start
- 2009-05
- Primary completion
- 2010-01
- Completion
- 2010-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Levodopa | Small molecule | 100 mg | Oral |
| Subject | XP21279 | Unknown | — | — |
| Comparator | Carbidopa | Unknown | 25 mg | Oral |